Stock Price
237.00
Daily Change
-3.30 -1.37%
Monthly
-8.39%
Yearly
49.48%
Q2 Forecast
229.11

UCB reported EUR1.47B in Selling and Administration Expenses for its fiscal semester ending in December of 2025.





Selling And Administration Expenses Change Date
Alcon AG USD 882M 19M Mar/2026
Amarin USD 18.97M 1.03M Dec/2025
argenx SE USD 355M 74.62M Mar/2026
AstraZeneca USD 5.06B 455M Mar/2026
Bayer EUR 3.7B 356M Mar/2026
Genmab DKK 208M 60M Dec/2025
GlaxoSmithKline GBP 2.12B 558M Mar/2026
GRIFOLS EUR 281M 5.7M Mar/2026
Hikma Pharmaceutical USD 288M 149M Dec/2025
Lakefront Biotherapeutics EUR 35.5M 8.91M Mar/2026
Merck EUR 1.6B 136M Dec/2025
Novartis USD 3.14B 296M Mar/2026
Orion EUR 91.9M 18.8M Mar/2026
Recordati EUR 187.24M 15.86M Dec/2025
Roche Holding CHF 7.28B 3.99B Dec/2025
Sanofi EUR 2.33B 419M Mar/2026
UCB EUR 1.47B 193M Dec/2025
Unibail Rodamco EUR 94.8M 4.8M Dec/2025